ADMA ADMA BIOLOGICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—
Margins
Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%
Returns
ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $141.10M | $124.39M | $114.49M | $139.16M | $134.22M | $121.98M | $114.80M | $117.55M |
| Cost of revenue | $41.19M | $38.12M | $33.74M | $50.35M | $58.60M | $54.76M | $53.70M | $54.22M |
| Gross profit | $99.92M | $86.28M | $80.75M | $88.82M | $75.63M | $67.23M | $61.10M | $63.33M |
| R&D expense | $4.49M | $6.01M | $2.60M | $1.38M | $1.53M | $1.03M | $826,000 | $391,000 |
| SG&A expense | $26.55M | $26.74M | $26.74M | $23.51M | $21.78M | $22.21M | $24.08M | $23.32M |
| Operating income | $67.76M | $52.45M | $58.27M | $62.75M | $51.01M | $42.80M | $34.88M | $38.32M |
| Interest expense | $3.43M | $3.42M | $2.10M | $1.63M | $1.68M | $1.83M | $1.98M | $2.88M |
| Pretax income | $65.60M | $50.24M | $57.13M | $61.59M | $47.52M | $40.10M | $33.45M | $34.71M |
| Income tax | $15.72M | $12.41M | $11.80M | $12.22M | $11.09M | $5.88M | $6.55M | -$77.18M |
| Net income | $49.88M | $37.82M | $45.33M | $49.38M | $36.43M | $34.22M | $26.90M | $111.90M |
| EBITDA | $69.46M | $54.15M | $60.07M | $64.75M | $53.01M | $44.80M | $36.78M | $40.32M |
| EPS (basic) | 0.22 | 0.17 | 0.19 | — | 0.15 | 0.14 | 0.11 | — |
| EPS (diluted) | 0.22 | 0.16 | 0.19 | — | 0.15 | 0.14 | 0.11 | — |
| Weighted avg. shares (diluted) | 225.82M | 230.34M | 239.96M | — | 244.66M | 248.61M | 244.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $124.56M | $136.02M | $138.15M | $87.63M | $61.38M | $90.28M | $71.62M | $103.15M |
| Receivables | $169.22M | $138.23M | $135.86M | $158.43M | $137.67M | $109.73M | $99.41M | $50.00M |
| Inventory | $266.12M | $239.31M | $222.10M | $206.47M | $196.67M | $191.46M | $172.19M | $170.24M |
| Current assets | $575.86M | $528.20M | $511.17M | $466.51M | $402.65M | $399.56M | $351.81M | $331.41M |
| PP&E, net | $66.76M | $66.66M | $65.01M | $65.06M | $69.51M | $57.50M | $57.71M | $54.71M |
| Goodwill | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M |
| Intangibles | $581,000 | $575,000 | $630,000 | $632,000 | $491,000 | $527,000 | $452,000 | $460,000 |
| Total assets | $732.49M | $684.21M | $665.18M | $624.24M | $568.69M | $558.38M | $510.57M | $488.68M |
| Current liabilities | $95.28M | $75.76M | $73.54M | $69.54M | $56.49M | $74.94M | $53.50M | $55.54M |
| Short-term debt | $4.22M | $3.75M | $3.28M | $2.81M | $2.34M | — | — | $0 |
| Long-term debt | $191.64M | $192.84M | $193.58M | $69.33M | $70.08M | $73.40M | $72.53M | $72.34M |
| Total debt | $195.86M | $196.59M | $196.87M | $72.14M | $72.43M | $73.40M | $72.53M | $72.34M |
| Total liabilities | $293.98M | $276.00M | $274.86M | $146.92M | $137.50M | $160.06M | $137.15M | $139.66M |
| Shareholders' equity | $438.51M | $408.21M | $390.32M | $477.32M | $431.19M | $398.32M | $373.42M | $349.02M |
| Net debt | $71.30M | $60.57M | $58.71M | -$15.49M | $11.04M | -$16.89M | $902,000 | -$30.81M |
| Shares outstanding | 222.79M | 225.36M | 232.29M | 237.87M | 238.33M | 238.57M | 238.53M | 236.62M |
| Cash flow statement | ||||||||
| Operating cash flow | $17.37M | $29.54M | $58.25M | $35.64M | $13.29M | $21.14M | -$19.68M | $50.22M |
| Capital expenditure | $2.00M | $2.26M | $2.54M | $1.08M | $14.37M | $2.42M | $4.70M | $2.76M |
| Free cash flow | $15.37M | $27.28M | $55.71M | $34.55M | -$1.07M | $18.72M | -$24.38M | $47.46M |
| Investing cash flow | -$2.07M | -$2.26M | $2.40M | -$276,000 | -$14.37M | -$2.53M | -$4.72M | -$2.75M |
| Financing cash flow | -$26.77M | -$29.42M | -$10.13M | -$9.12M | -$27.82M | $48,000 | -$7.13M | -$31.03M |
| Depreciation & amortization | $1.70M | $1.70M | $1.80M | $2.00M | $2.00M | $2.00M | $1.90M | $2.00M |
| Stock-based compensation | $6.20M | $6.13M | $6.33M | $5.39M | $5.05M | $4.96M | $4.62M | $5.43M |
| Share buybacks | $25.05M | $25.05M | $130.19M | $8.90M | $23.04M | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.